公开(公告)号：US20120244110A1

公开(公告)日：2012-09-27

申请号：US13425817

申请日：2012-03-21

Applicant: Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, JR. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

Inventor： Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, JR. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

IPC: A61K31/519 ,  A61K31/7068 ,  A61K31/704 ,  A61P35/02 ,  A61K31/573 ,  A61K39/395 ,  A61K38/19 ,  A61P35/00 ,  C07D471/14 ,  A61K31/664

CPC classification number: C07D519/00 ,  C07D471/14

Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.

Abstract translation: 式I化合物是CDK 4，CDK 6和FLT 3的有用抑制剂。 这些化合物可用于治疗癌症和各种其他疾病状况。 式I的化合物具有以下结构：其中R1是式IA，式IB，式IC或式ID的基团，并且本文提供了其它变量的定义。

公开(公告)号：US08623885B2

公开(公告)日：2014-01-07

申请号：US13425817

申请日：2012-03-21

Applicant: Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, Jr. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

Inventor： Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, Jr. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

IPC: A61K31/505 ,  C07D487/12

CPC classification number: C07D519/00 ,  C07D471/14

Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.

Abstract translation: 式I化合物是CDK 4，CDK 6和FLT 3的有用抑制剂。 这些化合物可用于治疗癌症和各种其他疾病状况。 式I的化合物具有以下结构：其中R1是式IA，式IB，式IC或式ID的基团，并且本文提供了其它变量的定义。